MID completes enrollment in STASIS trial of Permaseal

Micro Interventional Devices, Inc. has completed enrollment in its Secure Transapical Access and Closure Study. STASIS is a non-randomized, multi-center, CE-Mark study, evaluating the safety and performance of Permaseal the world's first automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).



from The Medical News http://ift.tt/1BQhkuE